TOKYO, August 1, 2023 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) constantly reviews its allocation of managerial resources, in order to adapt flexibly to the rapidly changing business environment and to reinforce its medium to long-term sustainable growth. Following a strategic review of our Japan commercial business, a decision has been taken to re-prioritize our portfolio to achieve medium to long-term growth in Japan. To support this, the company will build new capabilities with a focus on enhancing omnichannel engagement and data analytics, driven by the needs of its customers. By doing so, Astellas will deliver VALUE to patients who are waiting for the company’s innovative medicines.
Astellas has started discussions with the Labor Union today regarding initiating a Career Change Support Program (CCSP) for employees impacted by this transformation in sales management structure. The company plans to accept applications for the CCSP from December 2023 and to conclude it at the end of March 2024.
Anticipated costs for these measures are included in Astellas’ full-year financial forecast (ended March 2024), announced today.
Click below for a copy of the full press release
